We confirm that PRA-m/lEVs- and PRA-m/lEV-ICs-treated MDM produce elevated levels of proinflammatory cytokines and induced higher frequency of autologous CD69+ B cells in patients with RA compared to HD. This evidence concerns the gene S100A6 and rheumatoid arthritis.